For The Better

Lilly is staying ahead of the technology curve instead of falling behind.

Tilray is beaten down, but that alone doesn’t make it cheap.

Rocket Lab USA is still one of the market’s most promising space stocks.

Stock splits tend to be good news for a company. Will it be the same for Sony?

Charles Schwab’s survey indicates that crypto is evolving from a fringe asset class to a portfolio staple.

Chewy’s shares have been volatile, but your money has still grown over the last five years.

Tesla’s stock price hinges on its Robotaxi service, but you can get its biggest competitor practically for free.

Medical Properties Trust is moving past its challenges.

The average benefit varies widely by age, and research shows some filing ages are better than others.

Annaly Capital has a huge 13% dividend yield, but don’t buy it for the yield because the stock may end up letting you down in the long run.

These are two of healthcare’s biggest darlings right now, but one looks better positioned for the long run.

Each of these could be a millionaire-maker, and together they could be part of a supercharged growth portfolio.

It isn’t easy to be positive on the struggling company’s prospects.

Pfizer’s high dividend yield and robust pipeline could offer significant returns for patient investors.

The electric vehicle maker’s stock has been on the decline following the reveal of its self-driving robotaxi and humanoid robot Optimus.

Regulators are coming after Visa’s dominant role in the payments industry.

Bitcoin hit all-time highs earlier this year before paring some of those gains.

Enterprise Products Partners is one of the highest-quality, high-yielding dividend stocks.

These companies are rewarding their shareholders with dividends and capital gains.

Artificial intelligence is spreading through the corporate sector like wildfire.